Seattle Genetics Announces Proposed Public Offering of Common Stock
July 23 2019 - 4:09PM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it
has commenced an underwritten public offering of 6,000,000 shares
of its common stock. All of the shares are being offered by Seattle
Genetics. In addition, Seattle Genetics expects to grant the
underwriters of the offering a 30-day option to purchase up to an
additional 900,000 shares of its common stock solely to cover
overallotments at the public offering price, less the underwriting
discounts and commissions. The offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering will be completed, or as to the actual size or
terms of the offering.
Seattle Genetics anticipates using the net proceeds from the
offering to fund ongoing commercialization of ADCETRIS in the
United States and Canada, to fund its activities in preparation for
the potential commercial launch of enfortumab vedotin, if approved
by the FDA, to fund its research and development efforts designed
to further expand the ADCETRIS label and to advance its pipeline of
product candidates, as well as for general corporate purposes,
including working capital. Seattle Genetics may also use a portion
of the net proceeds to in-license, acquire or invest in
complementary products, technologies, businesses or other assets or
pursue other strategic opportunities although at this time Seattle
Genetics has no material agreements or commitments with respect to
any new in-license or acquisition opportunity.
J.P. Morgan Securities LLC, SVB Leerink LLC and Goldman Sachs
& Co. LLC are acting as joint book-running managers for the
offering.
A shelf registration statement relating to the shares was
previously filed with and became effective by rule of the
Securities and Exchange Commission. The offering is being made
solely by means of a prospectus. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the Securities and Exchange Commission and will
be available on the Securities and Exchange Commission's website
located at http://www.sec.gov. A copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering,
when available, may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at
prospectus-eq_fi@jpmchase.com; SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282, by
telephone at (866) 471-2526, by facsimile at (212) 902-9316 or by
email at Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Seattle Genetics
Seattle Genetics is a biotechnology company that develops and
commercializes therapies targeting cancer.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Seattle Genetics’
expectations regarding the completion, timing and size of the
public offering, its expectations with respect to granting the
underwriters a 30-day option to purchase additional shares and its
anticipated use of net proceeds from the offering. Actual results
or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause
such a difference include risks and uncertainties related to
completion of the public offering on the anticipated terms or at
all, market conditions and the satisfaction of customary closing
conditions related to the public offering. More information about
the risks and uncertainties faced by Seattle Genetics is contained
in the section captioned “Risk Factors” in the preliminary
prospectus supplement related to the public offering to be filed
with the Securities and Exchange Commission. Seattle Genetics
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190723005929/en/
Investors: Peggy Pinkston 425-527-4160 ppinkston@seagen.com or
Media: Monique Greer 425-527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024